Global Vaginitis Therapeutics Market to reach $8.2 billion by 2033, dominated by North America.
From GlobeNewswire: 2024-06-11 09:00:00
The Global Vaginitis Therapeutics Market is projected to grow from USD 3.7 billion in 2023 to USD 8.2 billion by 2033, with a CAGR of 8.28%. Vaginitis therapeutics aim to regulate symptoms of vaginal inflammation caused by bacterial vaginosis, candidiasis, and trichomoniasis.
Bacterial vaginosis dominates the market with the largest revenue share due to its common incidence among sexually active women. Antibiotics, especially metronidazole and clindamycin, are effective in treating vaginitis infections. Hospital pharmacies play a significant role in dispensing specialized treatments for severe or complex vaginal infections.
North America leads the market with the highest market share, driven by high disease prevalence, established healthcare infrastructure, and important manufacturers. The Asia-Pacific region is expected to accelerate growth due to unmet clinical needs, rising consumer income, and access to effective pharmaceuticals in countries like China and India. Major vendors in the market include Johnson & Johnson, GlaxoSmithKline, and Sanofi.
In July 2023, Dare Bioscience, Inc. announced the business launch of XACIATO vaginal gel in partnership with Organon, with a $1 million payment from Organon. The global vaginitis therapeutics market is segmented by disease type (bacterial vaginosis, candidiasis, trichomoniasis), drug class (anti-bacterial, anti-fungal, anti-protozoal), and distribution channel (hospital pharmacy, retail pharmacy, online pharmacy).
Spherical Insights & Consulting is a market research and consulting firm providing actionable insights for various industries. Their mission is to work with businesses to achieve strategic improvements and help decision-makers achieve their objectives. For more information on the market, contact Spherical Insights through email, phone, or their website.
Read more at GlobeNewswire: Global Vaginitis Therapeutics Market Size To Exceed USD 8.2